Anna M. Gasparri
Milan, Italy
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 20 publications
An αvβ6/αvβ8-targeting peptibody inhibits integrin-dependent TGFβ activation, enables tumor-selective cytotoxic delivery, and synergizes with PD-L1 immune checkpoint blockade.
Journal: Theranostics
Published: January 10, 2026
Blockade of αvβ6 and αvβ8 integrins with a chromogranin A-derived peptide inhibits TGFβ activation in tumors and suppresses tumor growth.
Journal: Journal of experimental & clinical cancer research : CR
Published: January 14, 2025
A novel aminopeptidase N/CD13 inhibitor selectively targets an endothelial form of CD13 after coupling to proteins.
Journal: Cellular and molecular life sciences : CMLS
Published: September 19, 2023
A simple and robust nanosystem for photoacoustic imaging of bladder cancer based on α5β1-targeted gold nanorods.
Journal: Journal of nanobiotechnology
Published: March 29, 2023
A stapled chromogranin A-derived peptide homes in on tumors that express αvβ6 or αvβ8 integrins.
Journal: International journal of biological sciences
Published: June 07, 2022
Enhancement of doxorubicin anti-cancer activity by vascular targeting using IsoDGR/cytokine-coated nanogold.
Journal: Journal of nanobiotechnology
Published: February 15, 2021
NGR-TNF Engineering with an N-Terminal Serine Reduces Degradation and Post-Translational Modifications and Improves Its Tumor-Targeting Activity.
Journal: Molecular pharmaceutics
Published: August 18, 2020
Boosting Interleukin-12 Antitumor Activity and Synergism with Immunotherapy by Targeted Delivery with isoDGR-Tagged Nanogold.
Journal: Small (Weinheim an der Bergstrasse, Germany)
Published: July 02, 2019
Glycine N-methylation in NGR-Tagged Nanocarriers Prevents Isoaspartate formation and Integrin Binding without Impairing CD13 Recognition and Tumor Homing.
Journal: Advanced functional materials
Published: October 06, 2017
Last Updated: 09/26/2026